IMPORTANCE The DRCR Retina Network Protocol S randomized clinical trial suggested that the mean visual acuity of eyes with proliferative diabetic retinopathy (PDR) treated with ranibizumab is not worse at 5 years than that of eyes treated with panretinal photocoagulation (PRP). Moreover, the ranibizumab group had fewer new cases of diabetic macular edema (DME) with vision loss or vitrectomy but had 4 times the number of injections and 3 times the number of visits. Although 2-year cost-effectiveness results of Protocol S were previously identified, incorporating 5-year data from Protocol S could alter the longer-term cost-effectiveness of the treatment strategies from the perspective of the health care system.

OBJECTIVE To evaluate 5- and 10-year cost-effectiveness of therapy with ranibizumab, 0.5 mg, compared with PRP for treating PDR.

DESIGN, SETTING, AND PARTICIPANTS A preplanned secondary analysis of the Protocol S randomized clinical trial using efficacy, safety, and resource utilization data through 5 years of follow-up for 213 adults diagnosed with PDR and simulating results through 10 years.

INTERVENTIONS Intravitreous ranibizumab, 0.5 mg, at baseline and as frequently as every 4 weeks based on a structured retreatment protocol vs PRP at baseline for PDR; eyes in both groups could receive ranibizumab for concomitant DME with vision loss.

MAIN OUTCOMES AND MEASURES Incremental cost-effectiveness ratios (ICERs) of ranibizumab therapy compared with PRP were evaluated for those with and without center-involved DME (CI-DME) and vision loss (Snellen equivalent, 20/32 or worse) at baseline.

RESULTS The study included 213 adults with a mean (SD) age of 53 (12) years, of whom 92 (43%) were women and 155 (73%) were white. The ICER of the ranibizumab group compared with PRP for patients without CI-DME at baseline was $582 268 per quality-adjusted life-year (QALY) at 5 years and $742 202/QALY at 10 years. For patients with baseline CI-DME, ICERs were $65 576/QALY at 5 years and $63 930/QALY at 10 years.

CONCLUSIONS AND RELEVANCE This study suggests that during 5 to 10 years of treatment, ranibizumab, 0.5 mg, as given in the studied trial compared with PRP may be within the frequently cited range considered cost-effective in the United States for eyes presenting with PDR and vision-impairing CI-DME, but not for those with PDR but without vision-impairing CI-DME. Substantial reductions in anti–vascular endothelial growth factor cost may make the ranibizumab therapy cost-effective within this range even for patients without baseline CI-DME.

TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT01489189
The DRCR Retina Network Protocol S 5-year outcomes showed that anti–vascular endothelial growth factor (anti-VEGF) therapy with ranibizumab, 0.5 mg, vs panretinal photocoagulation (PRP) for eyes with proliferative diabetic retinopathy (PDR) results in good mean visual acuity for eyes in both groups. Many of the outcomes at 2 years were sustained through 5 years, supporting the 2-year conclusion that ranibizumab therapy or PRP are both viable treatments for patients with PDR. The 5-year study had a high loss to follow-up in both groups, bringing into question whether the groups remained comparable at 5 years. Nevertheless, outcomes favoring the ranibizumab group included a decreased development of center-involved diabetic macular edema (CI-DME) associated with visual acuity loss (Snellen equivalent of 20/32 or worse) and a trend toward decreased development of retinal detachments. In contrast, outcomes favoring PRP included one-third the number of visits and one-quarter the number of injections. Only approximately 6% of eyes in each group had substantial visual acuity loss, and both groups experienced progressive visual field loss in years 3 through 5, diminishing the difference in visual field loss between the groups at 5 years compared with 2-year results. A smaller percentage of eyes in the ranibizumab group had a vitreous hemorrhage at 2 years, although 50% of the eyes in each group experienced at least 1 vitreous hemorrhage by 5 years.

The 2-year cost-effectiveness analysis of Protocol S showed that ranibizumab therapy compared with PRP was unlikely to be cost-effective for patients with PDR without CI-DME and vision loss but was possibly cost-effective for patients with PDR and CI-DME with vision loss who were receiving anti-VEGF therapy for DME. It was not appropriate to expand these findings across 5 to 10 years without knowing the visual acuity, number of visits and injections, incidence of CI-DME with vision loss, and safety outcomes beyond 2 years. The 5-year relative cost-effectiveness, from the health care system perspective, and an estimate of the 10-year cost-effectiveness using simulations based on 5-year outcomes may be calculated from the Protocol S 5-year results.

Methods
Overview
The DRCR Retina Network Protocol S randomized clinical trial was undertaken from February 2012 through February 2018 at 55 clinical sites in the United States. All participants had PDR in the study eye. In the efficacy analysis, both eyes were eligible; however, because it is difficult to allocate costs and improved quality-of-life by eye, this analysis included only 213 individuals with 1 study eye (70% of the study participants).

The ranibizumab group was treated as often as monthly, and the PRP group received PRP at baseline and supplemental PRP during follow-up if neovascularization worsened. All eyes could receive ranibizumab, 0.5 mg, for vision-impairing CI-DME. Analyses were conducted separately for individuals with and without vision-impairing CI-DME at baseline. Multiple institutional review boards approved the study, and all patients provided written informed consent to participate. The study protocol and the statistical analysis plan were previously published.

Analysis
Eyes had best-corrected visual acuity measured at baseline and every 16 weeks. The protocol specified collection of resource utilization related to ocular conditions and systemic adverse events for cost-utility analysis. Because the association of ocular use of anti-VEGF agents with systemic adverse events was not strong, costs of systemic adverse events were not included in the base analyses but were included in a sensitivity analysis. Data were collected through 5 years, and 95% CIs were calculated. Outcomes beyond the 5-year period were simulated up to a 10-year horizon. Assuming that vision remained constant, injections continued at the same frequency observed in year 5, and (in a sensitivity analysis) long-term serious adverse events that occurred in years 1 through 5 (cerebrovascular accident and myocardial infarction) continued to have long-term costs of care. These assumptions were varied in sensitivity analyses.

Costs
Costs were applied to the resources used that were captured in the trial. The unit costs, including physician and facility fees, were based on the 2018 Medicare fee schedule of allowable charges. A dose of ranibizumab, 0.5 mg, cost $1866.82; the injection procedure, $104.40; and PRP, $351.00. Costs were grouped into clinic visits or diagnostic procedures, study procedures, intraocular therapies, and (in the sensitivity analysis) systemic adverse events. Short- and long-term costs for cerebrovascular accidents and myocardial infarction were based on the literature. Costs were considered from the health system perspective and were measured in 2018 US dollars, and future costs were discounted by 3% annually (eTables 1 and 2 in the Supplement). Baseline characteristics of the study population are provided in eTable 3 in the Supplement.

Key Points

**Question** What is the incremental cost-effectiveness ratio of therapy with ranibizumab, 0.5 mg, compared with panretinal photocoagulation at 5- and 10-year horizons for treating patients diagnosed with proliferative diabetic retinopathy?

**Findings** This preplanned secondary analysis of a randomized clinical trial found that the estimated 10-year incremental cost-effectiveness ratio of the ranibizumab group compared with panretinal photocoagulation for those without center-involved diabetic macular edema at baseline is $742,202 per quality-adjusted life-year, and for those with baseline center-involved diabetic macular edema, $63,930 per quality-adjusted life-year.

**Meaning** This study’s findings suggest that, at the 5- and 10-year horizons, therapy with ranibizumab, 0.5 mg, may be within the frequently cited range considered cost-effective in the United States for treating patients with proliferative diabetic retinopathy and with baseline center-involved diabetic macular edema and vision loss but not for those without.
Health Utility
Health-related quality of life was measured using 2 methods. For the main analysis, visual acuities from the better-seeing eye at the 16-, 32-, 52-, 68-, 84-, 104-, 156-, 208-, and 260-week visits were converted into quality-adjusted life-years (QALYs) using the methods of Brown et al.2 and were compared with the baseline utility associated with the participant’s best-corrected visual acuity in the better-seeing eye at randomization (eTable 1 in the Supplement). This approach is commonly used but is limited by the top of the scale being anchored at perfect vision instead of perfect health.8 The second approach used the best-corrected visual acuities from the study eye and was anchored at perfect health.9 In both methods, if an observation was missing, the last observation was carried forward. The QALYs gained were discounted by 3% annually.

Extrapolation of Longer-term Results
Resource use, costs, and QALYs were aggregated across the 5 years of the trial based on observed data. Additional outcomes were simulated from years 5 through 10, making assumptions about continuing cost and vision. Rates of injections in year 5 in both groups were assumed to remain constant throughout years 6 through 10. Specifically, eyes in the ranibizumab group would continue to receive 3 ranibizumab injections per year and those in the PRP group would continue to receive a mean (SD) of 0.09 (0.283) ranibizumab injections per year for eyes without CI-DME and vision loss at baseline and a mean (SD) of 0.9 (0.276) injections per year for eyes with CI-DME and vision loss at baseline. In a sensitivity analysis, individuals who experienced serious systemic events in the first 5 years were assumed to have continuing care for those conditions through year 10. The last observed visual acuity (and utility) was assumed to remain the same through year 10. These assumptions were varied in sensitivity analyses.

The main outcome was the incremental cost-effectiveness ratio (ICER), which was calculated by taking the incremental total cost of the ranibizumab group vs the PRP group and dividing by incremental overall QALYs gained of ranibizumab vs PRP. The ICERs were computed for subgroups with and without concomitant baseline DME and vision loss. A lower ICER indicated better cost-effectiveness. Although there is no strict threshold for cost-effectiveness in the United States, values of $50 000, $100 000, and $150 000/QALY were focused on because they are frequently cited as values (unit costs and vision-to-utility conversion values). The Monte Carlo simulation used 10 000 iterations to create cost-effectiveness acceptability curves.

Results
The study included 213 adults with a mean (SD) age of 53 (12) years, of whom 92 (43%) were women, 121 (57%) were men, and 155 (73%) were white.

Costs
For participants without baseline CI-DME and vision loss over a 5-year period, the mean (SD) total costs were $8887 ($10 375) for the PRP group and $32 300 ($19 903) for the ranibizumab group (difference, $23 413 [95% CI, $18 567-$28 258]). For participants with baseline CI-DME and vision loss, the mean (SD) costs were $22 355 ($18 730) for the PRP group and $40 825 ($23 457) for the ranibizumab group (difference, $18 470 [95% CI, $6320-$30 619]). Costs increased during a 10-year period. For participants without baseline CI-DME and vision loss, the simulated mean (SD) cost for the PRP group was $9509 ($10 394) and $53 183 ($19 789) for the ranibizumab group (difference, $43 675 [95% CI, $38 849-$48 500]). For participants with baseline CI-DME and vision loss, the simulated mean total costs for participants in the PRP group were $28 889 ($18 928) and for the ranibizumab group, $60 979 ($21 667) (difference, $32 090 [95% CI, $20 486-$43 693]). Most costs were for the ranibizumab therapy or treatment of systemic adverse events (Table 1).

Health Utilities
For participants without CI-DME causing vision loss at baseline, the improvement from ranibizumab over PRP was 0.04 QALYs (95% CI, −0.019 to 0.099) at 5 years and 0.059 QALYs (95% CI, −0.059 to 0.177) at 10 years. For those with CI-DME causing vision loss at baseline, the improvement was 0.282 QALYs (95% CI, 0.11-0.454) at 5 years and 0.502 QALYs (95% CI, 0.169-0.835) at 10 years (Table 2). Differences using the QALY calculation method based on the treated eye showed similar or smaller differences (eTables 4 and 5 in the Supplement).

Cost-effectiveness
Treatment with ranibizumab vs PRP in participants without CI-DME at baseline causing vision loss had an ICER of $582 268/QALY at 5 years and $742 202/QALY at 10 years. For participants with CI-DME at baseline causing vision loss, the ICER of ranibizumab vs PRP was $65 576/QALY at 5 years and $63 930/QALY at 10 years. Estimates of the uncertainty in these values are presented in the next section with the probabilistic sensitivity analysis.

Sensitivity Analyses
A sensitivity analysis that included costs related to systemic adverse events was performed because rates of systemic adverse events were slightly higher in the ranibizumab group. The ICERs increased slightly once systemic adverse events were in-
Five-Year Cost-effectiveness of Ranibizumab vs Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

Table 1. Mean per-Patient Costs of Treatment With Ranibizumab, 0.5 mg, and PRP

<table>
<thead>
<tr>
<th>Variable</th>
<th>With Vision-Impairing CI-DME at Baselinea</th>
<th>Without Vision-Impairing CI-DME at Baseline</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PRP for PDR, Ranibizumab for CI-DME (n = 25)</td>
<td>Ranibizumab for PDR and CI-DME (n = 21)</td>
</tr>
<tr>
<td>At 5 y of follow-up, $</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinic visits/diagnostic procedures</td>
<td>1282</td>
<td>1954</td>
</tr>
<tr>
<td>PRP</td>
<td>351</td>
<td>16</td>
</tr>
<tr>
<td>Anti-VEGF injection procedureb</td>
<td>947</td>
<td>1916</td>
</tr>
<tr>
<td>Ranibizumab, 0.5 mg, therapy</td>
<td>16 925</td>
<td>34 264</td>
</tr>
<tr>
<td>Vitrectomies</td>
<td>1096</td>
<td>1336</td>
</tr>
<tr>
<td>Other intraocular therapiesc</td>
<td>1755</td>
<td>1338</td>
</tr>
<tr>
<td>Total (range)</td>
<td>22 555 (15 013-29 697)</td>
<td>40 825 (30 793-50 858)</td>
</tr>
<tr>
<td>Simulated 10 y, $</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Additional costs of ranibizumab injection procedures and drug</td>
<td>6534</td>
<td>20 154</td>
</tr>
<tr>
<td>Total (range)</td>
<td>28 089 (21 470-36 309)</td>
<td>60 979 (51 712-70 246)</td>
</tr>
</tbody>
</table>

Table 2. Change in QALYs and Cost-effectiveness Results (Utilities Converted From Visual Acuity in the Better-Seeing Eye)a

<table>
<thead>
<tr>
<th>Cost-effectiveness Parameter</th>
<th>With Vision-Impairing DME at Baselinea</th>
<th>Without Vision-Impairing CI-DME at Baseline</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PRP for PDR and Ranibizumab for CI-DME (n = 25)</td>
<td>Ranibizumab, 0.5 mg, for PDR and CI-DME (n = 21)</td>
</tr>
<tr>
<td>At 5 yb</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean costs (95% CI), $</td>
<td>22 355</td>
<td>40 825</td>
</tr>
<tr>
<td>QALYs (95% CI)</td>
<td>0.02</td>
<td>0.30</td>
</tr>
<tr>
<td>ICER, $</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>At 10 yd</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean costs (95% CI), $</td>
<td>28 889</td>
<td>60 979</td>
</tr>
<tr>
<td>QALYs (95% CI)</td>
<td>0.04</td>
<td>0.54</td>
</tr>
<tr>
<td>ICER, $</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

Abbreviations: CI-DME, center-involved diabetic macular edema; DME, diabetic macular edema; ICER, incremental cost-effectiveness ratio; PDR, proliferative diabetic retinopathy; PRP, panretinal photocoagulation; PDR, proliferative diabetic retinopathy; PRP, panretinal photocoagulation. a With visual acuity letter scores less than 78 (approximate Snellen equivalent, 20/32 or worse) at baseline. b Participants in all groups received ranibizumab, 0.5 mg, if they developed DME during the trial. c Includes treatment for ocular adverse events, such as endophthalmitis. d Includes treatment for visual acuity, letter scores were converted to Snellen equivalents; then to utility levels using the mapping from Brown et al.7

In I-way sensitivity analyses, most parameter changes resulted in an ICER for those with CI-DME and vision loss remaining between $50 000 and $85 000/QALY. However, if only 1.5 annual ranibizumab injections were required after the fifth year, the ICER for participants with CI-DME and vision loss would decrease to $43 854/QALY. If the utility associated with good vision (20/20 to 20/25) were better or utility with moderate vision loss (20/50 to 20/200) were worse, then the ICER for participants with CI-DME and vision loss would decrease to approximately $50 000/QALY (eTable 7a and eFigure 1 in the Supplement). The 1-way sensitivity analyses showed ranibizumab was not likely to be cost-effective for those without baseline CI-DME and vision loss. If only 1.5 annual ranibizumab injections were required after the fifth year, the ICER for participants without CI-DME and vision loss would decrease to $375 100/QALY (eTables 7a and 7b in the Supplement).
Figure 1. One-Way Sensitivity Analysis of Varying Cost of Anti–Vascular Endothelial Growth Factor (Anti-VEGF) Assuming Effectiveness of Ranibizumab, 0.5 mg

The incremental cost-effectiveness ratios of anti-VEGF therapy vs panretinal photocoagulation. Although there are no official thresholds of cost-effectiveness in the United States, interventions costing less than $50 000 to $150 000 may be considered cost-effective.² The orange line represents results for patients with center-involved diabetic macular edema (DME) and vision loss; the blue line, patients without center-involved DME and vision loss.

Two-way sensitivity analyses on price vs utility (eFigure 4 in the Supplement), utility vs effectiveness (eFigure 5 in the Supplement), and price vs effectiveness (eFigure 6 in the Supplement), showed conditions under which ranibizumab may be cost-effective for those with baseline CI-DME and vision loss (Figure 2B). eFigures 3a and 3b in the Supplement showed similar results using utility conversion based on the treated eye.

The cost-effectiveness acceptability curves generated as part of the probabilistic sensitivity analysis showed the probability that ranibizumab injections may be cost-effective for various levels of willingness to pay for QALYs while taking into account the overall parameter uncertainty. Figure 3 shows that ranibizumab injections have a 37% chance of being cost-effective at a threshold of $50 000/QALY, 82% at a threshold of $100 000/QALY, and 93% at $150 000/QALY for participants with CI-DME and vision loss. There was only a 9% chance that ranibizumab injections may be cost-effective at a high threshold of $250 000/QALY for those without CI-DME and vision loss. Similar results using utility conversion based on the treated eye are shown in eFigure 7 in the Supplement.

Discussion

Based on this analysis of Protocol S across a 5- or 10-year horizon, treatment with ranibizumab injections is likely to be cost-effective for patients with PDR and CI-DME causing vision loss at baseline for whom ranibizumab therapy would be administered to treat the DME. In contrast, it is unlikely that ranibizumab injections compared with PRP would be cost-effective for patients with PDR but without CI-DME causing vision loss at the time of initiating treatment for PDR across a 5- to 10-year horizon. Results are consistent with our prior analysis, which used study results through 2 years.³

The cost of ranibizumab is substantially associated with the cost-effectiveness of ranibizumab therapy for treating PDR. Although ranibizumab, 0.3 mg, is available and less expensive, Protocol S used ranibizumab, 0.5 mg; therefore, the costs of the 0.5-mg dose were used for this analysis. While use of the 0.3-mg dose may reduce costs, it is unknown how this dosage would alter the effectiveness of the drug; therefore, we cannot calculate with certainty how the use of ranibizumab, 0.3 mg, would have altered the ICERs reported in this study. It is also difficult to extrapolate this cost-effectiveness analysis to other readily available anti-VEGF agents, including aflibercept or bevacizumab because the 2- to 5-year outcomes of those agents with regard to visual acuity, number of visits or injections, incidence of DME with vision loss, vitrectomy for vitreous hemorrhage or traction retinal detachment, or peripheral visual field loss are unknown at this time. However, if other anti-VEGF agents were equally as effective as ranibizumab, 0.5 mg, but cost much less (eg, $50 per dose, which is close to the cost of intravitreous bevacizumab in the United States and in many other countries), then anti-VEGF therapy may be cost-effective even for those without DME causing vision loss at baseline (Figure 1 and eFigure 1 in the Supplement). In addition, ranibizumab may be more cost-effective for certain subgroups of patients with CI-DME. For example, for patients with greater fear concerning vision loss (lower utility with moderate vision loss), ranibizumab may be more cost-effective. For patients without CI-DME, we did not find subgroups for whom ranibizumab would be cost-effective.

The probabilistic sensitivity analysis (Figure 3 and eFigure 7 in the Supplement) showed that there is substantial uncertainty in the precise ICER of ranibizumab therapy vs PRP for patients with PDR and CI-DME causing vision loss at baseline. This is likely because there were only 46 patients enrolled whose 1 eye also had baseline CI-DME and vision loss.

Strengths and Limitations

We are unaware of other large randomized clinical trials with a follow-up of 5 years evaluating anti-VEGF vs PRP for PDR with which to compare these results. However, the strengths of this study include random assignment of a relatively large cohort, excellent adherence to treatment regimens with few protocol deviations that could likely alter the outcomes analyzed, and prospective collection of data for this preplanned secondary outcome on cost-effectiveness through 5 years. Considering the stability of visual acuity, number of injections, and number of PRP sessions in years 3 through 5, there is greater confidence to the assumptions made when simulating the 10-year cost-effectiveness results.
Limitations of this analysis include the large proportion of individuals in each group lost to follow-up, although post hoc analyses of these groups did not identify obvious differences among the 5-year completers in each group.1 Also, these 5-year results and simulations for 10-year horizons used best-corrected visual acuity in the better-seeing eye or the study eye as a surrogate for overall health-related quality of life. This surrogate outcome may not capture all aspects of quality of well-being associated with receiving these interventions and do not capture the effects of these therapies on measurements of peripheral visual fields. There are also concerns comparing utilities anchored at perfect vision with cost-effectiveness thresholds anchored at perfect health.8 When we used a method with utilities anchored at perfect health (eTable 5 in the Supplement), ranibizumab therapy became less cost-effective. Furthermore, only direct medical costs of select events were captured rather than other costs, such as caregiver burden, transportation costs to visits, and costs associated with time away from work. These latter variables may have an adverse effect on the cost-effectiveness in the ranibizumab group, which had a 3-fold greater number of injections and a 4-fold greater number of visits compared with the PRP group at 5 years. These additional burdens could make ranibizumab less desirable from the perspective of patients. In addition, when PRP was performed at the time of this study, there was a 90-day global period before payment for additional PRP could be given. In 2019, there reimbursement for PRP is much less, and the global period is 10 days. It is unclear how or whether these changes may affect costs associated with PRP in routine clinical care, but they do not affect the efficacy of PRP as performed in this study. An additional limitation, the number of eyes with CI-DME with vision loss at baseline was small in this study, although the sensitivity analyses, particularly the probabilistic sensitivity analysis, explore some of that uncertainty. Finally, as noted for the cost-effectiveness analysis at 2 years, the use of investigator discretion to assess CI-DME treatment after the baseline visit may affect these 5-year cost-effectiveness analyses.

Figure 2. Two-Way Sensitivity Analysis of Number of Annual Injections With and Without Baseline Center-Involved Diabetic Macular Edema (DME) and Vision Loss

The colors in the figures represent the incremental cost-effectiveness ratios (ICERs) of therapy with ranibizumab, 0.5 mg, vs panretinal photocoagulation (PRP). Although there are no official thresholds of cost-effectiveness in the United States, interventions costing less than $50 000 to $150 000 may be considered cost-effective.7 The color scales are an order of magnitude different.

Figure 3. Cost-effectiveness Acceptability Curves

Results of the Monte Carlo simulation, which simultaneously varied all parameter estimates and created synthetic populations of patients from the trial using bootstrapping. The lines represent the fraction of simulation iterations in which ranibizumab was cost-effective compared with panretinal photocoagulation (y-axis) at various levels of willingness to pay for quality-adjusted life-year (QALY) gains (x-axis). The orange line represents results for patients with center-involved diabetic macular edema (DME) and vision; the blue line, patients without center-involved DME and vision loss.
Conclusions

Our analysis suggests that ranibizumab, 0.5 mg, vs PRP as given in this trial for treating PDR is within the $50 000/QALY to $150 000/QALY range, which is frequently cited as cost-effective in the United States for eyes presenting with, but not for those without, PDR and CI-DME causing vision loss at 5 years and a simulated 10-year horizon. A lower price for an equally effective or more efficacious drug could also make anti-VEGF cost-effective as a PDR treatment for individuals without baseline CI-DME and vision loss. Because the 2- and 5-year outcomes from Protocol S support ranibizumab therapy or PRP as viable treatments for PDR, when patient-specific factors, including anticipated visit compliance, cost, and frequency of visits, are taken into account, this cost-effectiveness analysis through 5 years and simulated for a 10-year horizon may be considered when choosing treatments for PDR.

ARTICLE INFORMATION

Accepted for Publication: August 13, 2019.
Published Online: October 24, 2019.

Author Affiliations: Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor (Hutton, Stein); Department of Industrial and Operations Engineering, University of Michigan College of Engineering, Ann Arbor (Hutton); Institute for Healthcare Policy & Innovation, University of Michigan, Ann Arbor (Hutton, Stein); Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor (Stein); Jaeb Center for Health Research, Tampa, Florida (Glassman); Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland (Bressler); Editor, JAMA Ophthalmology (Bressler); Feinberg School of Medicine, Northwestern University, Chicago, Illinois (Jampol); Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts (Sun); Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts (Sun); CME Editor, JAMA Ophthalmology (Sun).

Author Contributions: Dr Hutton had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Hutton, Glassman, Bressler, Jampol, Sun.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Hutton, Glassman, Bressler, Jampol.

Critical revision of the manuscript for important intellectual content: Hutton, Stein, Bressler, Jampol, Sun.

Statistical analysis: Hutton.

Obtained funding: Glassman, Bressler, Jampol, Sun.

Administrative, technical, or material support: Glassman, Bressler, Jampol, Sun.

Supervision: Sun.

Conflict of Interest Disclosures: Drs Hutton and Sun reported receiving grants from the JABC Center for Health Research. Drs Stein, Glassman, and Jampol reported receiving grants from the National Eye Institute (NEI). Dr Glassman also reported receiving grants from Genentech and Regeneron and nonfinancial support from Regeneron. Dr Bressler reported receiving grants from Bayer, Genentech/Roche, Novartis, and Samsung Bioepis. Dr Sun also reported receiving grants from Boehringer Ingelheim, Genentech/Roche, and JDRF, equipment loaned for research from Adaptive Sensory Technologies, Boston Micromachines, and Optovue; nonfinancial support from Boehringer Ingelheim, Genentech/Roche, Merck, Novartis, and Novo Nordisk; and personal fees from Current Diabetes Reports (as the diabetic retinopathy section editor, 2008–2017). JAMA Ophthalmology (as CME editor), Merck, and Novartis. A complete list of all DRCT.net investigator financial disclosures can be found at http://www.drcr.net.

Funding/Support: This study was supported by grants EY23207 and EY18817 through a cooperative agreement from the NEI and the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH), US Department of Health and Human Services.

Role of the Funder/Sponsor: The NIH participated in overseeing the conduct of the study and review of the manuscript but not directly in the design and conduct of the study, nor in the collection, management, analysis, and interpretation of the data, or in the preparation of the manuscript or the decision to submit the manuscript for publication.

DRCR Retina Network members who participated in the Yaron trial sites are listed in order by number of subjects enrolled into the study. The number of subjects enrolled is noted in parenthesis preceded by the site location and the site name. Personnel are labeled for study investigator, C for coordinator, V for visual acuity technician, and P for photographer. Charlotte Eye, Ear, Nose and Throat Associates PA, Charlotte, North Carolina (21 participants). Justin C. Brown (I); Andrew N. Antoszyk (I); David Browning (I); Angela K. Price (C, V); Sherry L. Fredenburg (C, V); Jenna T. Herby (C, V); Meri F. Walker (C, V); Christina J. Fleming (C, V); Ashley A. McClain (C, V); Angelia S. Karow (V); Autumn C. Grupp (V); Kelly R. Gallagher (V); Sarah A. Ennis (V); Donna McClain (P); Joan P. Mondello (P); Autumn K. Finch (P); Kathryn Kimrey (P); Loraine M. Clark (P); Lisa A. Jackson (P); Lynn Watson (P); Jeff A. Kuropas (P); Robin Kerr (P); Swann J. Bojaj (P); Susananh J. Held (P); Uma M. Balasubramaniam (P); Michael D. McOwen (P); Matt Dunlap (P). Elman Retina Group PA, Baltimore, Maryland (16 participants): Michael J. Elman (I); Henry A. Leder (I); JoAnn Starr (C); Jennifer L. Belz (C); Charles K. Putzulo (C); Dena Y. Saaler-Firestone (P); Perel M. Simpson (V); Pamela V. Singleton (V); Jennifer L. Simmons (V); Teresa Coffey (V); Dallas R. Sandler (V); Ashley Davis (V); Ashley M. Metzger (P); Peter Sotirakos (P); Terri Vance (I); Yolanda Alt (P); R. Carrie (P); Elizabeth (P); Jennifer L. Belz (C); Rachel A. Walsh (C); Ginger J. Manhart (C); Jenny J. Tracy (C); Dietrich Riepen (P); Boris Corak (V); Chelsey A. Bravenc (V); Brandon Nguyen (V); Ryan M. Reid (V); Yong Ren (P); Christopher C. Stovall (P); Ben Ostrander (P). California Retina Consultants, Santa Barbara, California (12 participants): Dante J. Pieramici (I); Alessandro A. Castellari (I); Sarah Fishbein (C, V); Michelle S. Hanna (C, V); Erica D. Morasse (C, V); Gina Hong (C, V); Jack Gui (C); Lisha Wan (V); Melvin D. Rabena (C); Sara Esau (C, V); Jerry Smith (V); Kelly Avery (V); Layne J. Bone (V); Aimee Walker (P); Matthew Giust (P); Nitce L. Ruvalcaba (P); Aimee H. Shook (P). Coralino Retina Center, Columbus, South Carolina (10 participants): Jeffrey G. Gross (I); Michael A. Magee (I); Barron C. Fishburne (I); Amy M. Flowers (C, V); Chresten Ochieng (C, V); Riley Stroman (C, V); Angelique S.A. McDowell (V); Randall L. Price (P); Hunter Matthews (P). Texas Retina Associates, Lubbock, Texas (10 participants): Michael Shami (I); Sushma K. Vance (I); Yolanda Saldavars (C); Keri S. Neuling (C); Brenda K. Arrington (C, P, V); Ashiali Meeks (V); Natalie R. Garcia (V); Kayla Blair (P); Janet Medrano (P); Ginger K. Rhymes (P); Fort Lauderdale Eye Institute, Plantation, Florida (10 participants): Stuart K. Burgess (I); Tirso M. Lara (I); Noel H. Pereda (C, V); Cindy V. Fernandez (C, V); Evelyn Quincha (V); Deborah Davis (V); Karen Workman (P). New England Retina Associates PC, Burbank, Connecticut (10 participants): Nauman A. Chaudhry (I); Sumit P. Shah (I); Gregory M. Haffer (I); Emilya German (C); Laura A. Fox (C, V); JoAnna L. Pelletier (C); Jennifer M. Matteson (C); Shannan Mooreau (C); Kristin E. Brown (V); Michelle Esler (V); Allison Fontecco (V); Emily Morse (P); Marie Grace Lagliva (P); Justin A. Coclo (P); Greg McNamara (P); Stefanie R. DeGulis (P); Marissa L. Schef (P); Angela LaPre (P). Valley Retina Institute, McAllen, Texas (9 participants): Victor Hugo Gonzalez (I); Nehal R. Patel (I); Rohit Adyanthaya (I); Roberto Diaz-Roehena (I); Deyla Araya (C); Crystal A. Alvarez (C); Ruth Iachetta (C); Edna E. Cruz (C); Jessica Rodriguez (C); Gabriella Zavala (C); Keshaly J. Salinas (C); Tabitha Trevino (V); Kristyle R. Lozano (V); Karina Miranda (V); Monica R. Cantu (V); Maricela Garza (V); Hector Jasso (V); Rebecca R. Flores (V); Rachel Rodriguez (V); Samuel Alonso (P); Amanda L. Sandoval (P); Santos Garza (P); John Trevino (P); Lazaro Aguero
Five-Year Cost-effectiveness of Ranibizumab vs Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

Original Investigation Research

Linda Goings (P); Alexis L. Smith (P); Jennifer J. Steffens (P); Robert Prusak (P); Hillary Bernard (P); B. Keene (P); Cristina M. Brubaker (P); Christine M. M. Pavlica (I); Noelle S. Matta (C, V); Alyson Drury (V); Cecelia Rykena (V); Trina M. Nitzsche (P); DuBois (V); Vivian Tanner (V); Mary A. Ilc (V); Kim Joseph M. Coney (I); Lawrence J. Singerman (I); Llewelyn J. Rao (I); Jerome P. Schartman (I); Raquel Hernandez (V); DianaPovero (P); Jesse V); Kara E. Halsey (C, V); William H. Kiernan (V); Landaverde (C); Belinda A. Almanza (V); Brenda Cassie Cone (C); Stacy M. Supapo (C); Nubia Defrin (I); Marie V. Lampson (C); Heather Pratte (V); Joseph P. Walker (I); Eileen Knips (C, P); Natalie N. Oelrich (P); Raul E. Lince (P); Justin Walsh (P).
Recognizing the True Cost of Medical Spending—An Assessment of Ranibizumab for Retinal Disorders

Steven M. Kymes, PhD; David Vollman, MD

The discipline of economics has been called the dismal science by some. The moniker is well earned, because a primary question considered by economists is how goods are distributed in communities. The term goods refers to things that are valued, such as food, education, and housing (hence, they are said to be good). One of the certainties about something good is that there is more demand than supply, ensuring scarcity. This means that to obtain more of a desired good, individuals need to give up another good that is also desired. For instance, when a person buys a car, he or she gives up money that was earned by surrendering leisure time; so, the person trades leisure time for the car. When a young woman or man desires to become an ophthalmologist, she or he gives up 4 years of time in medical school and 4 years in an internship and residency that they could have spent pursuing another career. Given this constant focus on trade-offs, one can understand why economists are seen as practicing a dismal specialty.

Health is a good, and vision is an element of health. To obtain good vision, as with other kinds of health, requires trade-offs, and that is what the Diabetic Retinopathy Clinical Research Network (DRCR) Retina Network2 is bringing to light in their study in this issue of JAMA Ophthalmology. Since its US Food and Drug Administration approval in 2006, ranibizumab has provided life-changing improvement to people with a number of retinal disorders, including macular degeneration, diabetic retinopathy, and retinal vein occlusion. Given such success, it is no surprise that physicians would see it as the first-line treatment for all retinal diseases. But in this preplanned secondary analysis from the Protocol S DRCR Retina Network study,2 the investigators dem-

INVITED COMMENTARY

Kim (V); Kevin A. Ellerbe (P); Caroline Costa (P); Kenneth Boyd (P); Reta Coslovich (C); Elizabeth A. Liew (V); Alexandra Kline (V); S. Katherine DaSilva (V); Kevin J. Blinder (C); Amy S. Iverson (V); Jane Marie A. Brown (C); Rose Anna M. Vlahakis (C); Kevin E. Green (V); Richard A. Hinckley (P); Thomas W. Stone (I); John W. Kitchens (I); Joel M. Barra (C); Jessica L. Miner (C); Heather Dunlap (V); Lydia McRae (V); Hienmy Dang (V); Tim Monahan (C); Kelly To (V); Hienmy Dang (V); Tim Monahan (C); Kelly To (V). Additional Contributions: Genentech provided ranibizumab for the study and funds to the DRCR.net to defray the study’s clinical site costs. As per the DRCR.net Industry Collaboration Guidelines (available at http://www.drcr.net), the DRCR.net had complete control over the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

REFERENCES


© 2019 American Medical Association. All rights reserved.